Humacyte (HUMA) Research & Development (2020 - 2026)

Humacyte (HUMA) has reported Research & Development for 7 consecutive years, with $18.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 17.55% year-over-year to $18.1 million in Q2 2026; TTM through Jun 2026 was $69.5 million, a 14.22% decrease from a year earlier, with the FY2025 full-year figure at $69.3 million, down 21.78% from the prior year.
• Research & Development was $18.1 million for Q2 2026 at Humacyte, down from $19.5 million in the prior quarter.
• Over five years, Research & Development peaked at $23.8 million in Q2 2024 and troughed at $14.6 million in Q4 2025.
• A 5-year average of $18.6 million and a median of $18.3 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 40.19% in 2023 and slipped 29.29% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $15.0 million in 2022, then jumped by 34.92% to $20.2 million in 2023, then grew by 2.36% to $20.7 million in 2024, then fell by 29.29% to $14.6 million in 2025, then rose by 24.23% to $18.1 million in 2026.
• The last three Research & Development figures came in at $18.1 million (Q2 2026), $19.5 million (Q1 2026), and $14.6 million (Q4 2025), per Business Quant data.